Fig. 2

Triptolide inhibited the expression of miR-17-92 and miR-106b-25. a Representative heat map of microarray analyses of triptolide-treated HepG2 cells. Five groups of HepG2 cells were treated as follows: T1 (DMSO treated), T2 (100 nM for 12 h), T3 (100 nM for 24 h), T4(200 nM for 12 h), T5 (200 nM for 24 h). Each group contained three biological replicates. b The pie chart represented the proportion of all differentially expressed miRNAs induced by triptolide. c The top ten high intensity differentially expressed miRNAs induced by triptolide. d The genomic organization and primary transcript structures of human mir-17-92 and miR-106b-25. qRT-PCR was performed to validate the profile data. e The seed sequence of five differentially expressed miRNAs. f–g Triptolide significantly down-regulated the expression of indicated mature miRNAs (left panel) and primary transcripts (right panel). The bars represented mean ± standard error of the mean, n ≥ 3. P*<.05, **P<.01 (t test)